Wall Street Zen Downgrades Sana Biotechnology (NASDAQ:SANA) to Sell

Sana Biotechnology (NASDAQ:SANA) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

SANA has been the topic of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 8th. Citigroup reissued an “outperform” rating on shares of Sana Biotechnology in a report on Thursday, October 30th. Citizens Jmp upped their price target on Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 30th. JMP Securities set a $8.00 price objective on shares of Sana Biotechnology in a research report on Thursday, October 30th. Finally, Wedbush boosted their target price on shares of Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.33.

Sana Biotechnology Price Performance

Shares of NASDAQ SANA opened at $3.29 on Friday. The stock has a market cap of $876.36 million, a PE ratio of -3.39 and a beta of 1.94. Sana Biotechnology has a 1 year low of $1.26 and a 1 year high of $7.30. The firm has a fifty day moving average price of $4.20 and a 200-day moving average price of $3.50.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. On average, research analysts expect that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Investors Weigh In On Sana Biotechnology

A number of hedge funds have recently bought and sold shares of SANA. Bank of New York Mellon Corp lifted its position in Sana Biotechnology by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company’s stock valued at $578,000 after purchasing an additional 7,230 shares during the last quarter. Cerity Partners LLC lifted its holdings in shares of Sana Biotechnology by 200.3% in the 1st quarter. Cerity Partners LLC now owns 46,181 shares of the company’s stock valued at $78,000 after acquiring an additional 30,801 shares during the last quarter. CWM LLC grew its position in Sana Biotechnology by 290.7% in the first quarter. CWM LLC now owns 38,431 shares of the company’s stock worth $65,000 after acquiring an additional 28,595 shares in the last quarter. Skandinaviska Enskilda Banken AB publ increased its stake in Sana Biotechnology by 52.7% during the first quarter. Skandinaviska Enskilda Banken AB publ now owns 289,273 shares of the company’s stock worth $483,000 after acquiring an additional 99,801 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Sana Biotechnology by 60.0% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 56,298 shares of the company’s stock valued at $95,000 after purchasing an additional 21,102 shares during the period. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.